Gold stock Agnico Eagle Mines has passed a buy point and outperformed the S&P 500. Other gold stocks have entered the IBD 50.

We use our proprietary models to rate stocks quantitatively and qualitatively. Read here for an analysis of our top picks in ...

Travelers is trading just below a buy point as investors move out of growth options, choosing defensive plays.

Paola Papanicolaou, Head of Intesa Sanpaolo’s International Banks DivisionMILAN, March 17, 2025 (GLOBE NEWSWIRE) -- Speaking at the EIB Forum ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

Prabhudas Lilladher recommended accumulate rating on Pidilite Industries with a target price of Rs 3318 in its research ...

Other gold stocks have entered the IBD 50. There is no way of telling when the stock market ... While AEM is well-placed on a strong pipeline of growth projects, solid financial health and surging ...

Other gold stocks have entered the IBD 50. We recently published a list ... record revenues and robust cash margins, while navigating growth challenges and strategic opportunities for 2025.

The company continues to leverage its expertise in developing products that target one of the root causes of inflammation in chronic diseases, aligning with its global growth strategy to serve both ...

Other gold stocks have entered the IBD 50. We recently published a list ... record revenues and robust cash margins, while navigating growth challenges and strategic opportunities for 2025.

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

As long as the business is growing, the stock may bounce around in the near term, but it's almost certainly going to increase ...